FLORENCE - Ten students representing their respective schools recently participated in the Lauderdale County Spelling Bee using an online test platform developed by the National Spelling Bee officials. The tests
Triggering a Tumor Antiviral Immune Response in Patients With Triple-Negative Breast Cancer pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
Targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body s immune response.
A new study published in
Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection. Researchers suggest this mechanism could open new avenues for turning on the immune system in aggressive cancers like TNBC. We know therapeutics that partially interfere with RNA splicing can have a very strong impact on tumor growth and progression, but the mechanisms of tumor killing are largely unknown. In this study, we discovered that these therapeutics are modulators of anti-tumor immunity, said Dr. Trey Westbrook, corresponding author of the study, executive director o
Date Time
Triggering antiviral immune response in certain breast cancers
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection. Researchers suggest this mechanism could open new avenues for turning on the immune system in aggressive cancers like TNBC.
“We know therapeutics that partially interfere with RNA splicing can have a very strong impact on tumor growth and progression, but the mechanisms of tumor killing are largely unknown. In this study, we discovered that these therapeutics are modulators of anti-tumor immunity,” said Dr. Trey Westbrook, corresponding author of the study, executive director of the Therapeutic I
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body s immune response.